Research programme: oncolytic viruses - ViraTherapeuticsAlternative Names: VSV-GP
Latest Information Update: 17 Jul 2015
At a glance
- Originator ViraTherapeutics
- Class Oncolytic viruses
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated